Gene control life sciences company Syros Pharmaceuticals has raised its first ever round of funding with a $30m series A round from Flagship Ventures, Arch Venture Partners and WuXi PharmTech Corporate Venture Fund.
WuXi PharmaTech Corporate Venture, part of the eponymous China-based drugs maker, has participated in a $30 series A round of funding into US-based biotech start-up Syros Pharmaceuticals. Syros has also picked Nancy Simonian, formally of Millennium Pharmaceuticals, as chief executive.
Venture capital firms Flagship Ventures and Arch Venture Partners led the round with participation from undisclosed private investors.
The new funds will be used to accelerate the growth of its gene control regulators called super enhancers.
Syros Pharmaceuticals…
